July 28, 2016 9:32 AM ET

Biotechnology

Company Overview of Hawaii Biotech, Inc.

Company Overview

Hawaii Biotech, Inc., a biotechnology company, researches and develops prophylactic vaccines for infectious diseases. The company provides a recombinant proteins production platform that has application to the manufacture vaccines, diagnostic kits, and research tools. Its technology platform develops vaccines for various diseases, including West Nile, dengue, tick borne encephalitis, influenza, hepatitis C, malaria, Japanese encephalitis, Ebola, Eastern equine encephalitis, and others. The company also develops recombinant subunit protein vaccines focusing on the quality of recombinant protein produced and its impact on immunogenicity; and GPI-0100, a saponin adjuvant useful in helping to el...

99-193 Aiea Heights Drive

Suite 200

Aiea, HI 96701

United States

Founded in 1982

Phone:

808-486-5333

Fax:

808-792-1343

Key Executives for Hawaii Biotech, Inc.

Chief Executive Officer, President and Director
Chief Financial Officer and Chief Operations Officer
General Counsel, Vice President of Business Development, Secretary and Director
Age: 69
Director of Molecular Biology and Cell Culture
Compensation as of Fiscal Year 2016.

Hawaii Biotech, Inc. Key Developments

Hawaii Biotech, Inc. Receives Contract to Develop Dengue Vaccine

Hawaii Biotech, Inc. announced that the US Army SBIR Program awarded the company a Small Business Innovation Research Phase I contract to develop an effective dengue vaccine to protect military personnel against this potentially mission-aborting disease. Current leading dengue vaccine candidates in clinical trails offer only partial protection and long immunization periods. International travelers and military personnel being deployed to tropical or subtropical regions require more immediate and more complete immunity. Specifically, HBI will develop and test novel adjuvants to enhance the immunogenicity of an inactivated dengue vaccine candidate. This effort takes the initial steps toward developing the world's first vaccine capable of rapidly generating complete, lasting protection from dengue fever. In Phase I, HBI will select suitable adjuvant formulations and then demonstrate protective efficacy in a mouse model with a single dengue serotype. Upon successful completion of Phase I, HBI will be eligible to apply for Phase II funding that will continue development of the inactivated dengue vaccine candidate. This will include expanding the work to all four dengue serotypes to establish feasibility of the required tetravalent vaccine for dengue and additional preclinical efficacy studies. A successful Phase II outcome will provide the basis for advancement of the dengue vaccine into clinical trials needed for regulatory approval and commercialization. This contract was funded by the Army SBIR Program. The work is managed by the US Army Medical Research and Materiel Command under Contract No. W81XWH-15-C-0120 and will be managed and done in collaboration with the Viral and Rickettsial Diseases Department at the Naval Medical Research Center.

Soligenix Announces Collaboration with the University of Hawai'i at Manoa and Hawaii Biotech to Develop Heat Stable Ebola Vaccine

Soligenix, Inc. announced a collaboration agreement with Axel Lehrer, PhD of the Department of Tropical Medicine, Medical Microbiology and Pharmacology, John A. Burns School of Medicine (JABSOM), University of Hawai'i at Manoa (UH Manoa) and Hawaii Biotech, Inc. (HBI) to develop a heat stable subunit Ebola vaccine. Dr. Lehrer, a co-inventor of the Ebola vaccine with HBI, has shown proof of concept efficacy with subunit Ebola vaccines in non-human primates. Under the terms of the feasibility agreement, Soligenix will evaluate its proprietary vaccine thermostabilization technology, ThermoVax™, licensed from the University of Colorado, to stabilize components of the vaccine. Ultimately, the objective is to produce a thermostable Ebola vaccine for worldwide distribution that does not require cold storage. ThermoVax™ has been previously demonstrated to enhance thermostability of both ricin (RiVax™) and anthrax (VeloThrax™) subunit vaccines. The initial work on the potential Ebola vaccine will focus on a single protein subunit antigen. The most advanced Ebola vaccines involve the use of vesicular stomatitis virus (VSV) and adenovirus vectors – live, viral vectors which complicate the manufacturing, stability and storage requirements. Dr. Lehrer's vaccine is based on highly purified recombinant protein antigens, circumventing many of these manufacturing difficulties. Dr. Lehrer and HBI have developed a robust manufacturing process for the required proteins. Application of ThermoVax™ may allow for a product that can avoid the need for cold-chain distribution and storage, yielding a vaccine ideal for use in both the developed and developing world.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Hawaii Biotech, Inc., please visit www.hibiotech.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.